#USA #Southlake #Healthcare Costs #Renibus Therapeutics #RBT-1

Renibus Therapeutics Presents Findings on RBT-1 at SCA 2025

Renibus Therapeutics, a pioneering company in biopharmaceuticals focused on cardiac, renal, and metabolic diseases, has recently made headlines with its announcement regarding a poster presentation on its innovative drug, RBT-1. This presentation will take place at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA) from April 26-29, 2025, in Montreal.

RBT-1: A Groundbreaking Development

RBT-1 is a first-in-class preconditioning agent that is administered intravenously, designed to be given 24-48 hours before a patient undergoes non-emergent cardiac or valve surgery. Renibus has achieved significant milestones in its clinical trials, having recently completed a Phase 2 study in February 2023, which yielded positive results announced in May of the same year. Moreover, they have successfully concluded enrollment for the Phase 3 pivotal trial known as PROTECT, aimed at significantly reducing risks associated with post-operative complications following cardiac surgeries.

The U.S. FDA has granted Breakthrough and Fast Track Designations for RBT-1, affirming its potential impact on patient outcomes. The implications of these awards are substantial, indicating a promising pathway for advancing RBT-1 towards widespread clinical application.

Insights from Leadership

Jeffrey Keyser, RPh, JD, PhD, who serves as the President and CEO of Renibus, expressed enthusiasm about the ongoing developments. He stated, "We are excited to build on our recent momentum of achieving full enrollment in our Phase 3 PROTECT study with a poster presentation at SCA 2025 that we can share with the global anesthesiologist community."
Renibus has highlighted the crucial economic aspects tied to post-operative complications, emphasizing how RBT-1 could not only lessen complication rates but also lower healthcare costs associated with cardiovascular surgery, ultimately benefiting anesthesiologists and patients alike.

The Poster Presentation

At the SCA meeting, the poster is titled "Clinical and Economic Impact of RBT-1 on Post-operative Complications and Costs for CABG and Valve Surgery," and will be presented on April 27, 2025. Experts including Dr. Frans van Wagenberg will discuss a cost-analysis arising from the Phase 2 trial results, suggesting that RBT-1 not only offers protective effects but also reduces average expected costs overall for patients.

Looking Ahead

The ongoing Phase 3 trial includes an extensive one-year post-discharge follow-up, allowing for deeper evaluation of RBT-1's clinical and economic impacts. As Renibus continues their diligent research efforts, they aim to provide further data that could set new standards in surgical recovery practices.

About RBT-1

RBT-1, scientifically known as stannic protoporfin/iron sucrose, operates as a potent stimulator for anti-inflammatory and antioxidant pathways. It is currently undergoing evaluation in the Phase 3 PROTECT study, reinforcing its standing as a vital advancement for reducing post-operative complications among cardiothoracic surgery patients.

Renibus has various projects in development, including the oral drug Veverimer. This medication aims to provide new solutions for addressing critical health concerns, having already achieved FDA Orphan Drug Designation, showcasing the company's broader commitment to advancing medical treatments.

For more details on RBT-1 and Renibus Therapeutics, interested parties can visit their official website or connect with them on LinkedIn.